PET

NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Hospitals, Health Technology, Radiology, Pharmaceutical, Biotechnology, Jefferies, Actinium-225, Radiopharmaceutical, Therapy, Cancer, NorthStar, CDMO, PET, Growth, Medical imaging

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.

Key Points: 
  • NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit.
  • “2024 and the next several years are pivotal for NorthStar as we expand our capabilities in the rapidly growing radiopharmaceuticals industry,” said Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar Medical Radioisotopes.
  • Our radiopharmaceutical R&D lab is busy with both PET diagnostics and therapeutics work where sponsors are experiencing useful results as they work to improve upon their formulations and processes.
  • Please reach out to your Jefferies representative to schedule.

Americhem has earned the EcoVadis Silver Medal for Sustainability

Retrieved on: 
Friday, April 5, 2024
Other Manufacturing, Environment, Textiles, Climate Change, Chemicals, Plastics, Manufacturing, Alternative Energy, Sustainability, Energy, Carbon, PCR, Solar energy, Cold, Biophysical environment, Silver, Human rights, PET, Guarantee of origin, LCA, Wind, Life-cycle assessment, Water, Safety, Sustainable procurement, Certification

Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal.

Key Points: 
  • Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal.
  • EcoVadis is a globally recognized assessment platform that rates businesses' sustainability in various categories.
  • View the full release here: https://www.businesswire.com/news/home/20240404483358/en/
    Americhem has earned the EcoVadis Silver Medal for Sustainability (Graphic: Business Wire)
    The EcoVadis rating also covers a broad range of non-financial management systems including Environmental, Labor and Human Rights, Ethics, and Sustainable Procurement impacts.
  • Americhem would like to thank EcoVadis for their commitment to ensuring that companies remain conscious in their efforts toward a more sustainable future.

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment

Retrieved on: 
Monday, April 1, 2024
Other Health, Seniors, Other Science, Pharmaceutical, Research, Mental Health, Medical Devices, Hospitals, Consumer, Science, Clinical Trials, Managed Care, Medical Supplies, Biotechnology, Neurology, Health, Health Technology, Health Insurance, Brain, Deficit spending, Cognitive deficit, CSF, Patient, Evaluation, PET, Biomarker, University, Population Health Management, Cerebrospinal fluid, Diagnosis, Pathology

The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.

Key Points: 
  • The test helps healthcare providers better determine the presence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
  • The new research, “ Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment ,” used a budget impact model in a hypothetical 1 million-member health plan to assess the economic utility of the PrecivityAD blood test.
  • Overall, the PrecivityAD blood test was associated with a cost savings of $643 per Alzheimer’s disease case (9% cost savings) identified.
  • We believe the use of the PrecivityAD blood test in the clinical care pathway may prevent unnecessary testing, provide cost savings and reduce the burden on both patients and health plans.”

GCC Polyethylene Terephthalate Market Analysis Report 2024: PET's Role in Eco-Friendly Packaging Solutions and Versatility in Automotive Applications - Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Packaging, Recycling, Chemicals, Plastics, Automotive Manufacturing, Environment, Manufacturing, MEG, PTA, Urbanization, Growth, Sport, Application, Dow Chemical Company, International, COVID-19, SABIC, PET, Transport, Food, Private sector, RPET, Ethylene glycol, Supply, GCC, Vision 2030, Tourism, Drink, Water, Compound annual growth rate, Polyethylene terephthalate, JBF, Food safety, Food industry, Bottled water

GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.

Key Points: 
  • GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.
  • GCC PET supply is expected to reach 3.61 million ton by 2029, while GCC PET demand in 2023 stood at 2.20 million ton.
  • Polyethylene Terephthalate (PET), formed by combining purified terephthalic acid (PTA) or dimethyl terephthalate with modified ethylene glycol, exhibits notable impact resistance and ensures food safety.
  • The GCC Polyethylene Terephthalate (PET) market is characterized by a moderately concentrated landscape with several established players vying for market share.

New Findings From Sunbird Bio Reveal Significant Potential of Specific Tau Proteins to Serve as Blood-Based Biomarker for Alzheimer’s Disease

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Neurology, General Health, Research, Science, Biotechnology, Diagnosis, EV, Brain, Plasma, Conference, Dementia, EVS, CSF, Tau, Alzheimer's disease, Sunbird, AUC, Patient, PET, Biomarker, Traffic barrier, APEX, Cerebrospinal fluid, Protein, Neuron, Trial of the century, Aggregation, DSM-IV codes, Blood, Medical imaging

“These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.

Key Points: 
  • “These results validate the potential of EV-bound tau proteins to serve as reliable blood-based biomarkers in accurately detecting Alzheimer’s disease,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • “This confirmed correlation between EV-bound tau in the blood and tau tangles in the brain combined with the early validation of our new tau assays is incredibly exciting.
  • The Sunbird Bio study being shared at Tau2024 evaluated the potential of EV-bound tau proteins in the blood as a method of directly detecting the tau proteins that aggregate in the brain.
  • They then used Sunbird Bio’s new proprietary tau assays to distinguish between EV-bound and unbound soluble forms of tau in plasma.

GuidePoint Security Helps Organizations Address Data Privacy Requirements with Portfolio of Services

Retrieved on: 
Thursday, March 21, 2024
Data Management, Security, Technology, Software, Networks, Internet, Metric, Organization, Exercise, Digital, Information, Risk, U.S. state, GDPR, DSAR, Process, PET, Bill of Rights, IPO, GPC, Privacy, NIST, Architecture, HIPAA, Do Not Track, FERPA, Procedure, ISO, Federal, Legislation, Guidepoint, Online shopping

GuidePoint Security , a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, today announced the availability of its Data Privacy services, which are designed to help customers take control of their privacy operations.

Key Points: 
  • GuidePoint Security , a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, today announced the availability of its Data Privacy services, which are designed to help customers take control of their privacy operations.
  • These new data privacy laws will require companies to be accountable and to evaluate and ensure data protection addendums in their processes.
  • GuidePoint’s Data Privacy Services are tailored to meet an organization and its data privacy program at its current maturity level.
  • “We have developed a broad portfolio of data privacy services to meet a customer at their current maturity level,” said Scott Griswold, Practice Director - Governance Services, GuidePoint Security.

Evenflo® Launches Pivot® Troop™: America’s First Modular Travel System Designed for Children and Pets

Retrieved on: 
Tuesday, March 19, 2024
Parenting, Children, Other Retail, Baby, Maternity, Pets, Specialty, Consumer, Retail, Online Retail, Target, Child, WITH, PET, Travel, Infant, CHILD, Human, Target Corporation, Amazon (company), Safety, Product management, BPA, Pet, Family, Toy

Evenflo , designer, manufacturer, and marketer of infant and children’s products, announces the launch of the Pivot® Troop™ Child and Pet Modular Travel System, America’s first modular child and pet travel system designed to fit the whole family.

Key Points: 
  • Evenflo , designer, manufacturer, and marketer of infant and children’s products, announces the launch of the Pivot® Troop™ Child and Pet Modular Travel System, America’s first modular child and pet travel system designed to fit the whole family.
  • Seamlessly integrating the needs of both children and pets into one product, this innovation is a unique addition to Evenflo’s popular Pivot® collection .
  • “At Evenflo, we understand that families extend beyond humans, and this unique travel system reflects that.
  • Key features of the Pivot Troop include:
    TAKE YOUR WHOLE TROOP: The first travel system designed to fit both child and pet, making trips together convenient and fun for the entire family!

New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment

Retrieved on: 
Monday, March 18, 2024
Mental Health, Managed Care, Medical Devices, Hospitals, Neurology, Science, Medical Supplies, Clinical Trials, Biotechnology, Health, Health Technology, Health Insurance, Other Science, Research, Radiology, Pharmaceutical, Seniors, Radiation, APS2, Certification, Brain, Alzheimer's disease, Deficit spending, Disease, Memory, AUC, Patient, Ageing, PET, Journal, Apolipoprotein, City, CLIA, Pathology, Medicare, Amyloid, Medical imaging

The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.

Key Points: 
  • The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2 (APS2), was 0.94, yielding 88% agreement with brain amyloid status based on a single cut-off value.
  • The APS2 result was the most robust method among the individual plasma amyloid and tau analytes measured to identify disease.
  • In the published study, the PrecivityAD2 blood test was clinically validated in 583 individuals with cognitive impairment across two independent cohorts.
  • C₂N is working toward obtaining the requisite certification that will permit the PrecivityAD2 test to be available in New York in the near future.

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

Retrieved on: 
Thursday, April 4, 2024
PET/CT, Trailer, Patient, PET, Hospital, Nature, CDL, Medicare, Physician, Medical imaging

WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.

Key Points: 
  • WEXFORD, Pa., April 4, 2024 /PRNewswire/ -- CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer.
  • This cutting-edge mobile solution is designed to revolutionize cardiac care by directly providing state-of-the-art cardiac PET/CT imaging services to medical facilities on their schedule.
  • Positioned as a low-risk, high-value option, the Mobile Cardiac PET/CT Trailer is aimed at enhancing cardiac programs across various medical facilities and practices.
  • The Mobile Cardiac PET/CT Trailer marks CDL Nuclear Technologies' third flexible solution, which ranges from complete end-to-end PET/CT build-outs to mobile, on-demand daily use Rubidium-82 radioisotope services.